Scarica l'app Stockscreener
0.97
2.11%
0.02
Precedente Chiudi:
$0.95
Aprire:
$0.9392
Volume 24 ore:
798.07K
Relative Volume:
4.07
Capitalizzazione di mercato:
$45.62M
Reddito:
-
Utile/perdita netta:
$-51.47M
Rapporto P/E:
-0.97
EPS:
-1
Flusso di cassa netto:
$-47.50M
1 W Prestazione:
+10.45%
1M Prestazione:
+11.49%
6M Prestazione:
-38.99%
1 anno Prestazione:
-41.21%
Intervallo 1D:
$0.9392
$0.9914
Intervallo di 1 settimana:
$0.85
$0.9914
Portata 52W:
$0.81
$1.83
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Nome
Pmv Pharmaceuticals Inc
Settore
Industria
Telefono
(609) 642-6670
Indirizzo
400 ALEXANDER PARK DRIVE, PRINCETON
Confronta PMVP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
0.97 | 45.62M | 0 | -51.47M | -47.50M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-05-13 | Iniziato | Craig Hallum | Buy |
| 2024-04-12 | Iniziato | Jefferies | Buy |
| 2023-12-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-03-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-09-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-19 | Iniziato | Oppenheimer | Perform |
| 2021-08-02 | Iniziato | Guggenheim | Buy |
| 2021-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Cowen | Outperform |
| 2020-10-20 | Iniziato | Evercore ISI | Outperform |
| 2020-10-20 | Iniziato | Goldman | Neutral |
Mostra tutto
Pmv Pharmaceuticals Inc Borsa (PMVP) Ultime notizie
Northern Trust Corp Has $162,000 Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
PMV Pharmaceuticals to Participate at Upcoming Investor Conferen - GuruFocus
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences | PMVP Stock News - GuruFocus
PMV Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences on Oncology Innovation and Healthcare Advances - Nasdaq
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - GlobeNewswire
PMV Pharma CEO Reveals Latest Oncology Innovation Strategy at Two Major Healthcare Conferences - Stock Titan
D. E. Shaw & Co. Inc. Sells 16,189 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
These 3 Dividend Stocks Yield More Than 6% and Their Payouts Look Safe - The Globe and Mail
We're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Rate - Yahoo Finance
Crude Prices Rise on Doubts About a US-Iran Nuclear Deal - The Globe and Mail
Is Enbridge Stock Still Worth Owning After Strong Q1 Earnings? - The Globe and Mail
PMVP Advances PYNNACLE Trial with Steady Enrollment | PMVP Stock News - GuruFocus
PMV Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights | PMVP Stock News - GuruFocus
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewswire
PMVP Reports First Quarter Cash Position and Operational Spendin - GuruFocus
Randy A. Bowman Appointed Chairman of the Board at Westwood Holdings Group - The Manila Times
PMV Pharmaceuticals Reports Progress in Phase 2 PYNNACLE Trial and First Quarter 2025 Financial Results - Nasdaq
JPMorgan Chase & Co. Buys 23,559 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
In the Green: PMV Pharmaceuticals Inc (PMVP) Closes at 0.87, Up/Down -7.34 from Previous Day - DWinneX
I Update My Buy Recommendation for Reddit Stock - The Globe and Mail
PMV Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Nutshell gains IND clearance for p53 Y220C reactivator NTS-071 - BioWorld MedTech
Geode Capital Management LLC Sells 11,052 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
JPMorgan Chase & Co. Buys 336,516 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
PMV Pharmaceuticals stock hits 52-week low at $1.32 - MSN
ConocoPhillips (NYSE:COP) Receives Average Recommendation of “Buy” from Analysts - American Banking and Market News
APA Group (OTCMKTS:APAJF) Stock Price Down 9.1% – Here’s What Happened - Defense World
XP Power (OTCMKTS:XPPLF) Trading Down 12% – Should You Sell? - Defense World
PMV Pharmaceuticals (NASDAQ:PMVP) Stock Price Down 3.7% – Should You Sell? - Defense World
Dunxin Financial (NYSEAMERICAN:DXF) Stock Price Up 5.6% – Here’s What Happened - Defense World
Molecular Partners (OTCMKTS:MLLCF) Shares Down 1.4% – Should You Sell? - Defense World
PMV Pharmaceuticals patents new TP53 stabilizers - BioWorld MedTech
Alterome Therapeutics Announces New Chief Executive Officer and Chair of the Board of Directors - Business Wire
Promising Biotech Stocks To Watch Now – April 6th - Defense World
PMVP stock touches 52-week low at $1.01 amid market challenges - Investing.com Australia
PMV Pharmaceuticals stock hits 52-week low at $1.2 amid market shifts - Investing.com
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
HC Wainwright Reiterates “Buy” Rating for PMV Pharmaceuticals (NASDAQ:PMVP) - Defense World
Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace
PMVP stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
PMVP stock touches 52-week low at $1.2 amid market challenges By Investing.com - Investing.com South Africa
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing - Nasdaq
PMV Pharmaceuticals Reports Progress in Clinical Trials - TipRanks
PMV Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PMV Pharmaceuticals stock hits 52-week low at $1.32 By Investing.com - Investing.com South Africa
Pmv Pharmaceuticals Inc Azioni (PMVP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pmv Pharmaceuticals Inc Azioni (PMVP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mack David Henry | President and CEO |
Jan 03 '25 |
Option Exercise |
0.53 |
17,709 |
9,386 |
551,919 |
| Jalota Deepika | Chief Development Officer |
Sep 11 '24 |
Sale |
1.50 |
7,218 |
10,853 |
118,283 |
| Carulli Michael | Chief Financial Officer |
Sep 11 '24 |
Sale |
1.50 |
2,891 |
4,347 |
88,395 |
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):